Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet by Marsh, Jeremy et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Brief communication
Drug/diet synergy for managing malignant astrocytoma in mice: 
2-deoxy-D-glucose and the restricted ketogenic diet
Jeremy Marsh, Purna Mukherjee and Thomas N Seyfried*
Address: Biology Department, Boston College, Chestnut Hill, MA 02467, USA
Email: Jeremy Marsh - jmarsh@aecom.yu.edu; Purna Mukherjee - mukherjp@bc.edu; Thomas N Seyfried* - thomas.seyfried@bc.edu
* Corresponding author    
Abstract
Background: Astrocytomas are largely dependent on glycolysis to satisfy their bioenergetic
requirements for growth and survival. Therapies that target glycolysis can potentially manage
astrocytoma growth and progression. Dietary restriction of the high fat/low carbohydrate
ketogenic diet (KD-R) reduces glycolysis and is effective in managing experimental mouse and
human astrocytomas. The non-metabolizable glucose analogue, 2-deoxy-D-glucose (2-DG), is a
potent glycolytic inhibitor that can mimic effects of energy restriction both in vitro and in vivo, but
can also produce adverse effects when administered at doses greater than 200 mg/kg. The goal here
was to determine if low doses of 2-DG could act synergistically with the KD-R to better manage
growth of the CT-2A malignant mouse astrocytoma.
Methods: The therapeutic effect of a KD-R supplemented with a low dose of 2-DG (25 mg/kg)
was examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown
orthotopically. Mice were fed the standard unrestricted diet for the first 3 days after tumor
implantation prior to their separation into one of four diet groups fed either a standard rodent diet
in unrestricted amounts (SD-UR) or a KD-R with or without 2-DG for 10 days. The KD-R was
restricted to reduce body weight by about 20%. 2-DG was initiated 6 days after tumor implantation
and was continued for 7 days. Brain tumors were excised and weighed.
Results: Energy intake, body weights, and CT-2A tumor weights were similar in the SD-UR and
the SD-UR+2-2DG mouse groups over the dietary treatment period (days 3–13). Tumor weights
were about 48% and 80% lower in the KD-R and in the KD-R+2-DG groups, respectively, than in
the SD-UR group. Mouse health and vitality was better in the KD-R group than in the KD-R+2-DG
group.
Conclusion: Astrocytoma growth was reduced more in the KD-R mouse group supplemented
with 2-DG than in the mouse groups receiving either dietary restriction or 2-DG alone, indicating
a synergistic interaction between the drug and the diet. The results suggest that management of
malignant astrocytoma with restricted ketogenic diets could be enhanced when combined with
drugs that inhibit glycolysis.
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Background
Malignant astrocytomas represent a leading cause of can-
cer-related death [1-4]. The inability to effectively manage
these tumors has been due in part to the unique anatom-
ical and metabolic environment of the brain that prevents
the complete resection of tumor tissue and impedes the
delivery of therapeutic agents [5]. In contrast to normal
brain cells, which can metabolize both glucose and
ketone bodies for energy, brain tumors have a reduced
capacity to metabolize ketone bodies and, like most
malignant tumors, depend heavily on glycolysis for their
metabolic energy according to the Warburg cancer theory
[6-9]. Hence, therapies that can exploit the differences in
energy metabolism between normal brain cells and brain
tumor cells should be effective for tumor management
[5,6,9].
The high fat/low carbohydrate, ketogenic diet (KD) has
antiepileptic, anticonvulsant, and other neuroprotective
effects in rodent disease models and in humans [10-17].
A reduction of circulating glucose levels coupled with an
elevation of circulating ketone levels is thought to under-
lie the therapeutic effects [13,18,19]. Studies in children
and in experimental brain tumor models showed that the
KD administered in restricted amounts (KD-R) is effective
in managing tumor growth and in extending survival
[15,18,20]. The non-metabolizable glucose analogue 2-
deoxy-D-glucose (2-DG) is a potent glycolytic inhibitor
that can replicate effects of glucose deprivation in normal
cells and in cancer cells both in vitro and in vivo [21-25]. 2-
DG is readily transported into cells and is phosphorylated
by hexokinase, but cannot be metabolized further and
accumulates in the cell. This leads to ATP depletion and
the induction of cell-death. In this regard, 2-DG has been
described as a CR-mimetic, a drug that mimics some
aspects of calorie restriction [21,26]. Treatment of cancer
patients with relatively high doses of 2-DG (greater than
200 mg/kg) was largely ineffective in managing tumor
growth [27-29]. Side effects of 2-DG included elevated
blood glucose levels, progressive weight loss with leth-
argy, and behavioral symptoms of hypoglycemia [23,27-
29]. Reports that the ketogenic diet could be neuroprotec-
tive against hypoglycemic injury [12,16], and that it could
also inhibit brain tumor growth by reducing glucose
metabolism, suggest that combining the KD-R with low
doses of 2-DG (e.g. 25 mg/kg BW) might improve the effi-
cacy of the diet as an anticancer therapy. In the current
study, the effects of a KD-R supplemented with a low dose
of 2-DG were examined in adult C57BL/6J mice bearing
the syngeneic CT-2A malignant astrocytoma grown ortho-
topically.
Mice and Experimental Astrocytoma
Mice of the C57BL/6J (B6) strain were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA) and were
propagated in the Boston College Animal Care Facility as
previously described [30]. Adult male mice (~14 weeks of
age) were used in this study and were housed individually
in plastic cages with filter tops containing Sani-Chip bed-
ding (P.J. Murphy Forest Products Corp., Montville, NJ,
USA). The syngeneic malignant mouse astrocytoma was
implanted into the cerebral cortex as previously described
[31]. The procedures for animal use were in strict adher-
ence to the NIH Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal
Care Committee at Boston College. Other husbandry con-
ditions were as previously described [30].
Dietary Regimens, Body Weight, and Food Intake 
Measurements
Two types of dietary regimens were employed in the
study: the standard PROLAB RMH 3000 chow diet (SD)
(Lab Diet, Richmond, IN, USA) and the lard-based
ketogenic diet (KD) (Zeigler Bros., Inc., Gardners, PA,
USA). All mice received PROLAB RMH 3000 chow prior
to tumor implantation. The SD contained a balance of
mouse nutritional ingredients and delivers 4.1 kcal g-1
gross energy, where fat, carbohydrate, protein, and fiber
comprised 55, 520, 225, and 45 g kg-1 of the diet, respec-
tively. The KD also contained a balance of mouse nutri-
tional ingredients. According to the manufacturer's
specification, the KD delivers 7.8 kcal g-1 gross energy,
where fat, carbohydrate, protein, and fiber comprised
700, 0, 128, and 109 g kg-1 of the diet, respectively. The fat
in this diet was derived from lard and the diet had a
ketogenic ratio (fats: proteins + carbohydrates) of 5.48:1.
Body weight and food intake of all mice was recorded
daily (1:00 PM – 3:00 PM). Water was provided ad libitum
for all mice.
All mice were fed the standard diet unrestricted for the
first 3 days after tumor implantation. They were then sep-
arated into one of four diet groups fed either the standard
diet in unrestricted amounts (SD-UR) or a KD-R with or
without 2-DG (25 mg/kg) for 10 days. The four groups
were matched for body weight (~28.8 g) prior to the initi-
ation of the dietary regimens. Low dose treatment with 2-
DG was initiated 6 days after tumor implantation and was
continued for 7 days (Fig. 1B & Fig. 1C). The feeding par-
adigms for the KD-R and KD-R+2-DG groups were
designed to reduce mouse body weights by ~20% relative
to values recorded before the diets were initiated (3 days
after tumor implantation). All mice were euthanized 13
days after tumor implantation.
Results and discussion
Our goal was to determine if low doses of 2-DG, when
administered together with the KD-R, might produce syn-
ergistic effects. As our preliminary results showed that 2-
DG at doses exceeding 250 mg/kg produced adverseNutrition & Metabolism 2008, 5:33 http://www.nutritionandmetabolism.com/content/5/1/33
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effects to include weight loss, anorexia, and death (data
not shown), we chose 2-DG at a dose of 25 mg/kg because
this dosage did not alter food intake or body weight in
tumor-bearing mice fed the KD-R compared with mice fed
SD-UR. The therapeutic effects of dietary restriction arise
largely from caloric restriction per se and not from the
restriction of any specific dietary component such as pro-
teins, vitamins, mineral, fats, or carbohydrates [15,32-34].
We did not include an unrestricted KD (KD-UR) group or
a KD-UR+2-DG group in the study because we previously
showed that the rate of tumor growth in mice fed an unre-
stricted KD is similar to that of mice fed SD-UR [15].
Moreover, unrestricted feeding of either the KD or stand-
ard high carbohydrate diets maintains high glucose levels,
which provokes tumor angiogenesis and growth
[5,32,35,36]. Restricted KDs maintain higher circulating
ketone body levels and equally low glucose levels as
restricted high carbohydrate standard diets [13,18].
Administration of the KD in restricted amounts also
reduces adverse effects of the diet's high fat content, as fats
Influence of the restricted ketogenic diet with or without 2-DG on total energy intake (A), body weight (B), tumor growth  (C), and on cumulative survival (D) in mice bearing the orthotopically implanted CT-2A malignant astrocytoma Figure 1
Influence of the restricted ketogenic diet with or without 2-DG on total energy intake (A), body weight (B), 
tumor growth (C), and on cumulative survival (D) in mice bearing the orthotopically implanted CT-2A malig-
nant astrocytoma. All mice were fed the standard high carbohydrate rodent diet in UR amounts for the first 3 days after 
tumor implantation prior to their separation into one of four diet groups (n = 5–11 mice/group) fed either SD-UR or a KD-R 
with or without 2-DG (25 mg/kg) for 10 days. The four groups were matched for body weight. 2-DG was initiated 6 days after 
tumor implantation and was continued for 7 days (B &C). As shown in (B), the feeding paradigm for the KD-R and KD-R+2-
DG groups was designed to reduce body weights by ~20% relative to values recorded before the diet was initiated (3 days 
after tumor implantation). The average total energy intakes in (A) represent the number of kcals consumed by the indicated 
group over the dietary treatment period (day 3 to day 13). All values are expressed as the mean ± S.E.M. In (A &C), average 
values for the indicated group are significantly less than the average value for the SD-UR group at ** P < 0.01. The mean value 
for the KD-R+2DG group is significantly lower than the mean value for the KD-R group at † P < 0.01. No significant differ-
ences were observed between the SD-UR and SD-UR+2DG groups throughout the study. For (D), the number of tumor-bear-
ing mice that were alive in each group at the conclusion of the study is listed as a ratio above each solid vertical bar (e.g. the "6/
11" indicates that 6 of the 11 original mice were alive at the end of the study in the associated group).Nutrition & Metabolism 2008, 5:33 http://www.nutritionandmetabolism.com/content/5/1/33
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are rapidly converted to ketone bodies for tissue energy
metabolism [13]. Hence, we consider a restricted KD
more therapeutic for brain cancer management than
restricted high carbohydrate/protein diets. In contrast to
2-DG, which primarily reduces glycolysis through inhibi-
tion of hexokinase activity, dietary energy restriction acts
as a broad spectrum inhibitor of multiple metabolic and
signal transduction pathways without producing adverse
effects [5].
Total energy intake was similar over the dietary treatment
period (between 3 and 13 days after tumor implantation)
in the SD-UR+2-DG and SD-UR groups, but more varia-
bility was noticed in the SD-UR+2-DG group (Fig 1A).
Energy intake was similar between the KD-R and KD-R+2-
DG groups over the dietary treatment period. Body
weights were reduced to a similar degree (~20%) in the
two groups fed the KD-R (Fig. 1A & Fig. 1B). We previ-
ously showed that matching body weights within control
and treatment groups was absolutely critical for correct
data interpretation [13,18]. In the current study, we found
that administration of a low-dose of 2-DG had no signifi-
cant affect on either body weight or on CT-2A tumor
growth in mice fed the SD-UR (Fig. 1B & Fig. 1C). These
results contrast with those of Zhu et al., who showed that
administration of low dose 2-DG in an unrestricted stand-
ard high carbohydrate diet could reduce mammary tumor
growth in rats [21]. The differences in the results between
the two studies could be attributable to the different
rodent species used, the mode of drug delivery, or to the
location of the tumor (brain vs. subcutaneous flank).
We found that the average tumor weights for both the KD-
R and KD-R+2-DG groups were significantly lower than
those for the SD-UR group (48% and 80%, respectively)
(Fig. 1C). These observations are consistent with prior
studies showing that the KD-R can significantly reduce
orthotopic CT-2A tumor growth [15,18], and also provide
novel evidence that a low dose of 2-DG could act synergis-
tically with the KD-R to further reduce growth in this
mouse astrocytoma. The gross appearance of the mice
bearing the CT-2A tumors in the UR and R groups in this
study was similar to those that we showed previously for
the restricted standard and ketogenic diets [32]. While
tumor wet weight was reduced more in the KD-R + 2-DG
group than in the KD-R group, facial appearance and skull
size was similar in these groups. It is necessary to mention,
however, that the combined therapy produced adverse
effects on mouse health and vitality. Several mice in the
KD-R+2-DG group died while the survivors appeared
more lethargic than the mice in the KD-R group (Fig. 1D).
We suggest that energy stress was greater in mice receiving
the drug/diet combination than in mice receiving either
dietary restriction or 2-DG alone. Nevertheless, the results
show that 2-DG in combination with the restricted
ketogenic diet was synergistic with regard to tumor growth
and that potential adverse effects might be reduced with
adjustments in either drug concentration or in diet restric-
tion. Further studies will be needed to test this hypothesis.
Conclusion
Our findings provide novel evidence that the KD-R sup-
plemented with a low dose of 2-DG was effective in reduc-
ing intracerebral tumor growth to a greater extent than
was either 2-DG or the KD-R administered alone, suggest-
ing a synergistic interaction between the drug and the diet.
Although health and vitality were not as strong in the
drug/diet group than in the KD-R group, adjustments in
either 2-DG concentration or in dietary restriction could
mitigate health detrimental effects. Our results suggest
that combining drugs that inhibit glycolysis with
restricted ketogenic diets could enhance inhibition of
malignant astrocytoma growth.
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